On October 12, 2022 OSE Immunotherapeutics SA reported that three posters have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting which will be held in person and virtually in Boston, MA, November 8 – 12 (Press release, OSE Immunotherapeutics, OCT 12, 2022, View Source [SID1234646961]). The posters will feature the latest preclinical data on the Company’s pioneering drug discovery BiCKI and Myeloid platforms and including BiCKI-IL-7 (bifunctional therapy targeting PD-1 and IL-7) and CLEC-1 (new myeloid immune checkpoint). The Company was also invited for an oral presentation at the Macrophage-directed Therapies Summit of its CLEC-1 program (Boston, October 2022).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
POSTER PRESENTATION DETAILS AT THE SITC (Free SITC Whitepaper) 2022
BiCKI-IL-7v program
– Title: "IL7R TME expression correlates with immunotherapy response and is associated with Tcell stemness with decreased apoptosis" (poster #826)
Presentation date: November 11, 2022
– Title: "Anti-PD-1/IL-7v bispecific antibody promotes TCF1+ stem like T cells expansion and longlasting in vivo efficacy" (poster #1366)
Presentation date: November 11, 2022
CLEC-1 program*
– Title: "Blockade of the myeloid CLEC-1 checkpoint enhances antitumor responses and tumor antigen cross-presentation" (abstract #484)
Presentation date: November 11, 2022
ORAL PRESENTATION AT THE MACROPHAGE-DIRECTED THERAPIES SUMMIT 2022
– Title: "The C-type Lectin CLEC-1 is a Sensor of Cell Death Limiting Myeloid Cell Functions and Anti-Tumor Immunity"
Presentation date: October 4, 2022